Lyell Immunopharma (NASDAQ: LYEL) — Perfil da empresa, notícias e dados financeiros
Lyell Immunopharma pioneers T cell therapies for cancer treatment, focusing on enhancing efficacy and durability.
Lyell Immunopharma
Lyell Immunopharma (NASDAQ:LYEL) focuses on pioneering treatments in the field of cancer immunotherapy, working tirelessly to develop innovative T cell therapies aimed at solid tumors. While it's solely listed on the NASDAQ market, Lyell Immunopharma's projects revolve around the convergence of cell engineering and its applications in combating cancer, striving to enhance the efficacy and durability of T cell therapies. The company's objectives are anchored in leveraging cutting-edge science to create a robust pipeline of transformative cancer treatments, with the ultimate aim of achieving long-lasting remissions for patients battling various forms of the disease. Their work is a testament to their commitment to revolutionizing cancer care through scientific discovery and therapeutic innovation.
Resumo
Operações
Produtos e/ou serviços de Lyell Immunopharma
- Developing T-cell therapies aimed at solid tumors, utilizing unique reprogramming techniques to enhance efficacy.
- Collaborating on enhancing CAR-T therapies for improved persistence and potency in cancer treatment.
- Investigating the mechanisms of T-cell exhaustion to devise novel interventions and enhance immunotherapies.
- Pioneering the use of next-generation sequencing and machine learning to identify T-cell receptor repertoires for solid tumors.
- Focusing on the integration of synthetic biology to construct engineered T-cells with superior anti-tumor activity.
- Advancing techniques for the ex vivo expansion of tumor-infiltrating lymphocytes to boost their effectiveness in patient treatments.
equipe executiva do Lyell Immunopharma
- Richard D. KlausnerFounder & Executive Chairman
- Lynn SeelyPrincipal Executive Officer, President, CEO & Director
- Stephen J. HillChief Operating Officer
- Gary K. LeeChief Scientific Officer
- Stanley R. RiddellFounder & Scientific Advisor
- Crystal L. MackallFounder & Scientific Advisor
- Smital ShahPrincipal Financial Officer, CFO & Chief Business Officer
- Nellie DilleryDirector of Accounting
- Mark A. MeltzGeneral Counsel & Corporate Secretary
- Ann TomlinChief Human Resources Officer
Últimas notícias sobre a Lyell Immunopharma
Principais indicadores financeiros
Resultados divulgados pela Lyell Immunopharma, em USD.
- Cap. de mercado
- 267,8 mi
- Receita (TTM)
- 27 mil
- P/L
- —
- LPA (diluído, TTM)
- -12.9
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 36 mil | -203,8 mi | -274,4 mi | |
| 61 mil | -358,8 mi | -343 mi | |
| 130 mil | -247 mi | -234,6 mi | |
| 84,7 mi | -187,1 mi | -183,1 mi |